Company profile
Sichuan Kelun Pharmaceutical Co., Ltd.
002422 · SZSE (Shenzhen) (This is the PARENT company (Chengdu, founded 1996, publicly listed on Shenzhen Stock Exchange as 002422.SZ). It is a distinct entity from the roster's company_id 1040 'Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.' (ticker 6990, HKEX), which is Kelun Pharmaceutical's separately-listed majority-owned oncology subsidiary. Not the same sponsor as the trial-registry example listing shares an LEI/other-id pattern with Kelun-Biotech, but the legal entities are different and each has its own listing — flagging so the roster is not mistakenly merged. Sources: https://clinicaltrials.gov/study/NCT06674694 ; https://api.gleif.org/api/v1/lei-records/984500G84CRC0D4B3920 ; https://api.gleif.org/api/v1/lei-records/984500CE07P48BCA4D79 ; https://finance.yahoo.com/quote/002422.SZ/profile/ ; https://www.marketscreener.com/quote/stock/SICHUAN-KELUN-PHARMACEUTI-11367147/ Entity resolved by asset-pipeline-v2.)
Public Market Listing
Live quotes, historical charts, and market capitalization for Sichuan Kelun Pharmaceutical Co., Ltd. are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule | Schizophrenia |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.